Amedisys (Nasdaq: AMED) reported earnings on Nov. 6. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended Sep. 30 (Q3), Amedisys met expectations on revenues and beat expectations on earnings per share.

Compared to the prior-year quarter, revenue was unchanged and GAAP earnings per share expanded.

Gross margins shrank, operating margins dropped, net margins increased.

Revenue details
Amedisys logged revenue of $375.6 million. The 11 analysts polled by S&P Capital IQ anticipated a top line of $380.0 million on the same basis. GAAP reported sales were 0.2% higher than the prior-year quarter's $374.9 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
EPS came in at $0.33. The 11 earnings estimates compiled by S&P Capital IQ predicted $0.27 per share. GAAP EPS were $0.33 for Q3 compared to -$14.73 per share for the prior-year quarter.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 43.0%, 210 basis points worse than the prior-year quarter. Operating margin was 3.9%, 60 basis points worse than the prior-year quarter. Net margin was 2.6%, 11,560 basis points better than the prior-year quarter.

Looking ahead
Next quarter's average estimate for revenue is $381.7 million. On the bottom line, the average EPS estimate is $0.25.

Next year's average estimate for revenue is $1.51 billion. The average EPS estimate is $1.02.

Investor sentiment
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 817 members out of 910 rating the stock outperform, and 93 members rating it underperform. Among 220 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 187 give Amedisys a green thumbs-up, and 33 give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Amedisys is hold, with an average price target of $13.56.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.